| |
| Xpention
Genetics, Inc. is
a biotechnology company that was formed to develop both immunological
and molecular tests for cancer detection in animals and humans
as well as therapeutic vaccines and other treatment methods
for both veterinary and human cancers. Xpention through its
subsidiary has licensed, exclusive rights to a specific genetic
marker called the p65 that has highly specific correlation
to numerous cancers. |
| |
 |
|
|
|
|
| |
| |
|
|
| |
| Xpention
Genetics Signs Development Contract with GeneThera Inc. |
| |
06/28/05 :
Xpention Genetics, Inc. contracts GeneThera,
Inc. to develop a molecular diagnostic
cancer test for use on canines. The cancer test will use Xpention's
licensed p65 technology from the University of Texas MD Anderson
Cancer Center. P65 is a promising marker for the early detection
of malignant tumor formation and a useful tool for monitoring therapy
and remission. Levels of p65 also appear to have a direct correlation
to tumor mass/size.
In addition to the immunological test which
gives a yes or no result, a molecular test will be able to measure
the level of expression
of the p65 protein allowing its use as a confirmatory test and
enabling doctors to determine the effectiveness of treatments.
GeneThera, Inc. is a molecular biotechnology company which provides
genetic diagnostic solutions for the veterinary, agricultural,
and health-care industries. Their proprietary diagnostic solution
is based on a genetic expression assay, GEA(tm), a protocol designed
to function on a highly automated Fluorogenic PCR platform. David
Kittrell, CEO commented, ``The contract with Genethera to develop
a molecular cancer detection test for canines that is complementary
to the immunological test represents the next step in our business
plan to produce a comprehensive line of both diagnostic and therapeutic
products based on our licensed p65 technology.'' |
|
